Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation.

Boutin L, Arnautou P, Trignol A, Ségot A, Farge T, Desterke C, Soave S, Clay D, Raffoux E, Sarry JE, Malfuson JV, Lataillade JJ, Le Bousse-Kerdilès MC, Anginot A.

Haematologica. 2019 Jul 9. pii: haematol.2018.214379. doi: 10.3324/haematol.2018.214379. [Epub ahead of print]

2.

Macrophages Driving Heterotopic Ossification: Convergence of Genetically-Driven and Trauma-Driven Mechanisms.

Levesque JP, Sims NA, Pettit AR, Alexander KA, Tseng HW, Torossian F, Genêt F, Lataillade JJ, Le Bousse-Kerdilès MC.

J Bone Miner Res. 2018 Feb;33(2):365-366. doi: 10.1002/jbmr.3346. Epub 2017 Dec 27. No abstract available.

3.

Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications.

Torossian F, Guerton B, Anginot A, Alexander KA, Desterke C, Soave S, Tseng HW, Arouche N, Boutin L, Kulina I, Salga M, Jose B, Pettit AR, Clay D, Rochet N, Vlachos E, Genet G, Debaud C, Denormandie P, Genet F, Sims NA, Banzet S, Levesque JP, Lataillade JJ, Le Bousse-Kerdilès MC.

JCI Insight. 2017 Nov 2;2(21). pii: 96034. doi: 10.1172/jci.insight.96034.

4.

Peripheral denervation participates in heterotopic ossification in a spinal cord injury model.

Debaud C, Salga M, Begot L, Holy X, Chedik M, de l'Escalopier N, Torossian F, Levesque JP, Lataillade JJ, Le Bousse-Kerdilès MC, Genêt F.

PLoS One. 2017 Aug 30;12(8):e0182454. doi: 10.1371/journal.pone.0182454. eCollection 2017.

5.

Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients.

Ojeda-Uribe M, Morel O, Ungureanu C, Desterke C, Le Bousse-Kerdilès MC, Boulahdour H.

Cancer Med. 2016 Sep;5(9):2378-84. doi: 10.1002/cam4.835. Epub 2016 Aug 12.

6.

Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.

Desterke C, Martinaud C, Ruzehaji N, Le Bousse-Kerdilès MC.

Mediators Inflamm. 2015;2015:415024. doi: 10.1155/2015/415024. Epub 2015 Nov 12. Review.

7.

Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis.

Martinaud C, Desterke C, Konopacki J, Vannucchi AM, Pieri L, Guglielmelli P, Dupriez B, Ianotto JC, Boutin L, Lataillade JJ, Le Bousse-Kerdilès MC.

Genom Data. 2015 Apr 29;5:1-2. doi: 10.1016/j.gdata.2015.04.017. eCollection 2015 Sep.

8.

Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis.

Martinaud C, Desterke C, Konopacki J, Pieri L, Torossian F, Golub R, Schmutz S, Anginot A, Guerton B, Rochet N, Albanese P, Henault E, Pierre-Louis O, Souraud JB, de Revel T, Dupriez B, Ianotto JC, Bourgeade MF, Vannucchi AM, Lataillade JJ, Le Bousse-Kerdilès MC.

Cancer Res. 2015 Nov 15;75(22):4753-65. doi: 10.1158/0008-5472.CAN-14-3696. Epub 2015 Sep 24.

9.

Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Desterke C, Martinaud C, Guerton B, Pieri L, Bogani C, Clay D, Torossian F, Lataillade JJ, Hasselbach HC, Gisslinger H, Demory JL, Dupriez B, Boucheix C, Rubinstein E, Amsellem S, Vannucchi AM, Le Bousse-Kerdilès MC.

Haematologica. 2015 Jun;100(6):757-67. doi: 10.3324/haematol.2014.118497. Epub 2015 Apr 3.

10.

Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle.

Genêt F, Kulina I, Vaquette C, Torossian F, Millard S, Pettit AR, Sims NA, Anginot A, Guerton B, Winkler IG, Barbier V, Lataillade JJ, Le Bousse-Kerdilès MC, Hutmacher DW, Levesque JP.

J Pathol. 2015 Jun;236(2):229-40. doi: 10.1002/path.4519. Epub 2015 Mar 26.

PMID:
25712044
11.

In vivo hypobaric hypoxia performed during the remodeling process accelerates bone healing in mice.

Durand M, Collombet JM, Frasca S, Begot L, Lataillade JJ, Le Bousse-Kerdilès MC, Holy X.

Stem Cells Transl Med. 2014 Aug;3(8):958-68. doi: 10.5966/sctm.2013-0209. Epub 2014 Jun 18.

12.

CXCR7 participates in CXCL12-induced CD34+ cell cycling through β-arrestin-dependent Akt activation.

Torossian F, Anginot A, Chabanon A, Clay D, Guerton B, Desterke C, Boutin L, Marullo S, Scott MG, Lataillade JJ, Le Bousse-Kerdilès MC.

Blood. 2014 Jan 9;123(2):191-202. doi: 10.1182/blood-2013-05-500496. Epub 2013 Nov 25.

13.

SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

Malfuson JV, Boutin L, Clay D, Thépenier C, Desterke C, Torossian F, Guerton B, Anginot A, de Revel T, Lataillade JJ, Le Bousse-Kerdilès MC.

Leukemia. 2014 Apr;28(4):853-64. doi: 10.1038/leu.2013.256. Epub 2013 Sep 3.

PMID:
23999380
14.

Primary myelofibrosis and the "bad seeds in bad soil" concept.

Le Bousse-Kerdilès MC.

Fibrogenesis Tissue Repair. 2012 Jun 6;5(Suppl 1):S20. doi: 10.1186/1755-1536-5-S1-S20. eCollection 2012.

15.

FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

Desterke C, Bilhou-Nabéra C, Guerton B, Martinaud C, Tonetti C, Clay D, Guglielmelli P, Vannucchi A, Bordessoule D, Hasselbalch H, Dupriez B, Benzoubir N, Bourgeade MF, Pierre-Louis O, Lazar V, Vainchenker W, Bennaceur-Griscelli A, Gisslinger H, Giraudier S, Le Bousse-Kerdilès MC; French Intergroup of Myeloproliferative Disorders,; French INSERM; European EUMNET Networks on Myelofibrosis.

Cancer Res. 2011 Apr 15;71(8):2901-15. doi: 10.1158/0008-5472.CAN-10-1731. Epub 2011 Apr 12. Erratum in: Cancer Res. 2011 Jun 1;71(11):4049-50.

16.

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

Baran-Marszak F, Magdoud H, Desterke C, Alvarado A, Roger C, Harel S, Mazoyer E, Cassinat B, Chevret S, Tonetti C, Giraudier S, Fenaux P, Cymbalista F, Varin-Blank N, Le Bousse-Kerdilès MC, Kiladjian JJ, Velazquez L.

Blood. 2010 Dec 23;116(26):5961-71. doi: 10.1182/blood-2009-12-256768. Epub 2010 Sep 24.

17.

[Are stem cells as old as their niches? The quest for eternal life...].

Lataillade JJ, Brunet de la Grange P, Uzan G, Le Bousse-Kerdilès MC.

Med Sci (Paris). 2010 Jun-Jul;26(6-7):582-5. doi: 10.1051/medsci/2010266-7582. French. No abstract available.

18.

Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment.

Pierre-Louis O, Clay D, Brunet de la Grange P, Blazsek I, Desterke C, Guerton B, Blondeau C, Malfuson JV, Prat M, Bennaceur-Griscelli A, Lataillade JJ, Le Bousse-Kerdilès MC.

Stem Cells. 2009 Oct;27(10):2552-62. doi: 10.1002/stem.186.

19.

A boost of BMP4 accelerates the commitment of human embryonic stem cells to the endothelial lineage.

Goldman O, Feraud O, Boyer-Di Ponio J, Driancourt C, Clay D, Le Bousse-Kerdiles MC, Bennaceur-Griscelli A, Uzan G.

Stem Cells. 2009 Aug;27(8):1750-9. doi: 10.1002/stem.100.

20.

Tissue inhibitors of matrix metalloproteinases in platelets and megakaryocytes: a novel organization for these secreted proteins.

Villeneuve J, Block A, Le Bousse-Kerdilès MC, Lepreux S, Nurden P, Ripoche J, Nurden AT.

Exp Hematol. 2009 Jul;37(7):849-56. doi: 10.1016/j.exphem.2009.03.009. Epub 2009 May 3.

PMID:
19410025
21.

A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin.

Chabanon A, Desterke C, Rodenburger E, Clay D, Guerton B, Boutin L, Bennaceur-Griscelli A, Pierre-Louis O, Uzan G, Abecassis L, Bourgeade MF, Lataillade JJ, Le Bousse-Kerdilès MC.

Stem Cells. 2008 Dec;26(12):3150-61. doi: 10.1634/stemcells.2008-0219. Epub 2008 Aug 28.

22.

Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence.

Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyré MC, Le Bousse-Kerdilès MC; French INSERM and the European EUMNET Networks on Myelofibrosis.

Blood. 2008 Oct 15;112(8):3026-35. doi: 10.1182/blood-2008-06-158386. Epub 2008 Jul 31. Review.

23.

Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review.

Le Bousse-Kerdilès MC, Martyré MC, Samson M.

Eur Cytokine Netw. 2008 Jun;19(2):69-80. doi: 10.1684/ecn.2008.0127. Epub 2008 Jun 1. Review.

24.

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.

Chaligné R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socié G, Bordessoule D, Le Bousse-Kerdilès MC, Vainchenker W, Giraudier S.

Leukemia. 2008 Aug;22(8):1557-66. doi: 10.1038/leu.2008.137. Epub 2008 Jun 5.

PMID:
18528423
25.

Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis.

Bogani C, Ponziani V, Guglielmelli P, Desterke C, Rosti V, Bosi A, Le Bousse-Kerdilès MC, Barosi G, Vannucchi AM; Myeloproliferative Disorders Research Consortium.

Stem Cells. 2008 Aug;26(8):1920-30. doi: 10.1634/stemcells.2008-0377. Epub 2008 May 29.

26.

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, Levine R, Le Bousse-Kerdiles MC, Wadleigh M, Campbell PJ, Silver RT, Vannucchi AM, Deeg HJ, Gisslinger H, Thomas D, Odenike O, Solberg LA, Gotlib J, Hexner E, Nimer SD, Kantarjian H, Orazi A, Vardiman JW, Thiele J, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).

Leuk Res. 2007 Jun;31(6):737-40. Epub 2007 Jan 8. Review.

PMID:
17210175
27.

Expression of HMGA2 in PB leukocytes and purified CD34+ cells from controls and patients with Myelofibrosis and myeloid metaplasia.

Andrieux J, Bilhou-Nabera C, Lippert E, Le Bousse-Kerdiles MC, Dupriez B, Grardel N, Pierre-Louis O, Desterke C, Praloran V, Laï JL, Demory JL.

Leuk Lymphoma. 2006 Sep;47(9):1956-9. No abstract available.

PMID:
17065012
28.

Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1).

Guglielmelli P, Zini R, Bogani C, Salati S, Pancrazzi A, Bianchi E, Mannelli F, Ferrari S, Le Bousse-Kerdilès MC, Bosi A, Barosi G, Migliaccio AR, Manfredini R, Vannucchi AM.

Stem Cells. 2007 Jan;25(1):165-73. Epub 2006 Sep 21.

29.

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR.

Blood. 2006 Nov 15;108(10):3548-55. Epub 2006 Jul 27.

30.

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT.

Blood. 2006 Mar 1;107(5):2098-100. Epub 2005 Nov 17.

31.

Stem cell dysregulation in myelofibrosis with myeloid metaplasia: current data on growth factor and transcription factor involvement.

Martyré MC, Le Bousse-Kerdilès MC; members of the French INSERM Research Network on Myelofibrosis With Myeloid Metaplasia.

Semin Oncol. 2005 Aug;32(4):373-9. Review.

PMID:
16202683
32.

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, Gisslinger H, Griesshammer M, Hasselbalch H, Kusec R, Le Bousse-Kerdiles MC, Liberato NL, Marchetti M, Reilly JT, Thiele J; European Myelofibrosis Network.

Blood. 2005 Oct 15;106(8):2849-53. Epub 2005 Jun 30.

33.

Phenotypic and functional characteristics of CD34+ cells are related to their anatomical environment: is their versatility a prerequisite for their bio-availability?

Lataillade JJ, Clay D, David C, Boutin L, Guerton B, Drouet M, Hérodin F, Le Bousse-Kerdilès MC.

J Leukoc Biol. 2005 May;77(5):634-43. Epub 2005 Jan 26.

PMID:
15673546
35.

IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.

Emadi S, Clay D, Desterke C, Guerton B, Maquarre E, Charpentier A, Jasmin C, Le Bousse-Kerdilès MC; French INSERM Research Network on MMM.

Blood. 2005 Jan 15;105(2):464-73. Epub 2004 Sep 28.

36.

Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.

Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B.

J Clin Oncol. 2004 Feb 1;22(3):424-31.

PMID:
14752066
37.

Altered transcription of the stem cell leukemia gene in myelofibrosis with myeloid metaplasia.

Steunou V, Le Bousse-Kerdilès MC, Colin-Micouin A, Clay D, Chevillard S, Martyré MC; French INSERM Research Network on Myelofibrosis Myeloid Metaplasia.

Leukemia. 2003 Oct;17(10):1998-2006.

PMID:
14513050
38.

Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis?

Bilhou-Nabéra C, Brigaudeau C, Clay D, Andrieux J, Lai JL, Brouty-Boyé D, Vignon C, Gharbi MJ, Le Bousse-Kerdilès MC, Praloran V; French INSERM Network o Myeloid Metaplasia with Myelofibrosis.

Blood. 2003 Aug 15;102(4):1551-2. No abstract available.

39.

Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells.

Giron-Michel J, Fogli M, Gaggero A, Ferrini S, Caignard A, Brouty-Boye D, Baouz S, Le Bousse-Kerdiles MC, Peault B, van Dijk M, Bulfone-Paus S, Durali D, Chouaib S, Azzarone B.

J Exp Med. 2003 Mar 17;197(6):763-75.

40.
41.

Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.

Le Bousse-Kerdilès MC, Martyré MC; French INSERM research network on Idiopathic Myelofibrosis.

Pathol Biol (Paris). 2001 Mar;49(2):153-7. Review.

PMID:
11317961
42.

Effects of human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues on CD34+ stem cells.

Brouty-Boyé D, Briard D, Azzarone B, Le Bousse-Kerdilès MC, Clay D, Pottin-Clémenceau C, Jasmin C.

Int J Cancer. 2001 May 15;92(4):484-8.

43.

CD9 and megakaryocyte differentiation.

Clay D, Rubinstein E, Mishal Z, Anjo A, Prenant M, Jasmin C, Boucheix C, Le Bousse-Kerdilès MC.

Blood. 2001 Apr 1;97(7):1982-9.

44.

Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Le Bousse-Kerdilès MC, Martyré MC.

Springer Semin Immunopathol. 1999;21(4):491-508. Review. No abstract available.

PMID:
10945038
45.

Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: possible role in progenitor survival.

Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, Le Bousse-Kerdilès MC.

Blood. 2000 Feb 1;95(3):756-68.

46.
47.

Differential expression of protein kinase C isoform transcripts in human hematopoietic progenitors undergoing differentiation.

Oshevski S, Le Bousse-Kerdilès MC, Clay D, Levashova Z, Debili N, Vitral N, Jasmin C, Castagna M.

Biochem Biophys Res Commun. 1999 Oct 5;263(3):603-9.

PMID:
10512725
48.

Phenotypic diversity in human fibroblasts from myelometaplasic and non-myelometaplasic hematopoietic tissues.

Brouty-Boyé D, Doucet C, Clay D, Le Bousse-Kerdiles MC, Lampidis TJ, Azzarone B.

Int J Cancer. 1998 May 29;76(5):767-73.

49.

Implication of a new molecule IK in CD34+ hematopoietic progenitor cell proliferation and differentiation.

Cao LX, Le Bousse-Kerdiles MC, Clay D, Oshevski S, Jasmin C, Krief P.

Blood. 1997 May 15;89(10):3615-23.

50.

Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis.

Martyré MC, Le Bousse-Kerdiles MC, Romquin N, Chevillard S, Praloran V, Demory JL, Dupriez B.

Br J Haematol. 1997 May;97(2):441-8.

PMID:
9163611

Supplemental Content

Loading ...
Support Center